Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy for Metastatic Urothelial Carcinoma With Stable or Responding Disease Following Platinum-based Chemotherapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Lurbinectedin (Primary) ; Dexamethasone; Granulocyte colony-stimulating factor receptor agonists; Ondansetron
Indications Carcinoma; Urogenital cancer
Focus Therapeutic Use

Most Recent Events

31 Jul 2024 According to ClinicalTrials.gov record , this trial was withdrawn as PI Decision based on no enrollment
31 Jul 2024 Status changed from recruiting to withdrawn prior to enrolment.
08 May 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight